WEX Pharmaceuticals Inc. is a publicly listed
company (TSX:WXI) focused on the development and commercialization
of innovative drug products, primarily for pain management. WEX's lead compound, Tetrodotoxin, a sodium channel blocker, is
the platform for the Company's development of a portfolio of proprietary
products in the field of analgesia, drug addiction withdrawal
treatment, and local anaesthesia.